AYTU BIOPHARMA, INC quarterly report, Q1 FY2014

Business context and reporting period

Entity and period: The supplied filing is Rosewind Corporation’s unaudited Form 10-Q for the quarter ended November 30, 2013, not a filing identified as Aytu Biopharma. Rosewind describes itself as a development-stage offshore sailing instruction business. Its fiscal year ends August 31.

The company reports $5,250 of revenue since inception and says its student-revenue model remains unproven. The filing notes four training voyages, while its risk-factor discussion says it has trained six students and located only three paying students.

Key financial metrics

At November 30, 2013, cash was $445, total assets $7,164, current liabilities $133,387, and shareholders’ deficit $126,223. Working capital was negative $132,835. Related-party loans payable were $104,951, secured by the sailing vessel, bearing 6% interest, and due on demand; related-party accrued interest was $14,873. The filing does not provide a clear standalone margin measure, and margins are not meaningful with no quarterly revenue.

Material changes versus the prior comparable period

• Quarterly net loss narrowed by $3,352 (about 17%) to $16,507; management attributes the improvement primarily to lower boat repair and maintenance, management, and professional-fee costs.
• Interest expense increased 46% to $1,500 as the related-party loan balance grew.
• Operating cash use improved by $2,058. Cash nevertheless fell by $1,417 during the quarter to $445, after $5,441 of new related-party borrowing.
• Accounts payable rose to $12,763 from $6,842, and related-party loans rose to $104,951 from $99,510 since August 31, 2013.

Outlook, commentary, risks, and unusual items

• Going concern: The company reports losses since inception, limited operating history, and insufficient cash to sustain the business. It plans to seek additional equity funding, but gives no assurance it can raise funds. Management warns cash is not sufficient to sustain operations.
• Business outlook: No quantified guidance is provided. Management expects ongoing costs for vessel maintenance, upgrades, administration, and marketing, and says profitability depends on sufficient sailing-school revenue.
• Key risks: Limited demand and marketing experience; reliance on one officer/director and key personnel; potential dilution from future financing; vessel, voyage, safety, and under-insurance exposure; and possible licensing or regulatory requirements in jurisdictions outside the United States.
• Tax and regulatory contingencies: The company describes an $800 annual California business expense allowance and a disputed Alameda County personal-property tax assessment relating to the vessel. The amount and outcome of the disputed assessment are not clear in the filing. It also warns that unpaid assessments could result in collection action or liens.
• Related-party and equity items: The sole officer/director provided $1,140 of services and rent during the quarter, recorded as contributed capital. The company issued 20,000 shares to settle a $3,000 stock subscription.
• Management said disclosure controls were effective and reported no material changes in internal control over financial reporting. The statements are unaudited.

Important facts for investors to verify

1. Confirm the issuer: the supplied document names Rosewind Corporation, not Aytu Biopharma, Inc.
2. Reconcile the filing’s descriptions of voyages and student counts, including the statement of four voyages, six students trained, and three paying students located.
3. Verify near-term funding availability and the status, terms, and repayment demands of the $104,951 related-party loan and accrued interest.
4. Determine the amount and status of the Alameda County tax dispute, California tax obligations, and any vessel licensing requirements.
5. Assess whether the company can obtain adequate insurance and generate student revenue sufficient to continue operations.